Markets · 1 sources covering this

Novo Plunges as Investors Seek More Robust Sales Targets

Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports. (Source: Bloomberg)

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

BloombergLean L·2h ago
Novo Plunges as Investors Seek More Robust Sales Targets
Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports. (Source: Bloomberg)
Read at Bloomberg →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/4f23ad8a8aa90733253e7646e00c300598534d97"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Novo Plunges as Investors Seek More Robust Sales Targets"></iframe>

Novo Plunges as Investors Seek More Robust Sales Targets

How 1 sources are covering this